Latest news
SKYSCRAPER-03 Trial: Critical Setback for TIGIT Consolidation in Stage III NSCLC - OncodailyOncodaily · Sat, 08 Aug 2026 11:36:12 GMTVGCC Antibody Testing in Small Cell Lung Cancer: Assays, Interpretation, and the Seronegative Patient - onclive.comonclive.com · Fri, 07 Aug 2026 20:36:55 GMTJazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTSystImmune doses first patient in Phase III trial for ES-SCLC - Clinical Trials ArenaClinical Trials Arena · Thu, 06 Aug 2026 10:25:17 GMTDr Choudhury on Understanding Mechanisms of Resistance to DLL3-Directed BiTEs in SCLC - onclive.comonclive.com · Wed, 05 Aug 2026 22:10:51 GMTNew drug offers hope for small cell lung cancer patients - WKRCWKRC · Wed, 05 Aug 2026 21:32:03 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 14:09:23 GMT